×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Acute Myeloid Leukemia

Jessica Skarzynski
The COVID-19 pandemic has created a unique challenge for patients with myelodysplastic syndromes and acute myeloid leukemia, creating many questions that experts tried to answer in a recent webinar from The Aplastic Anemia and MDS International Foundation.
 
Conor Killmurray
The COVID-19 pandemic will continue to alter how patients with cancer receive their treatment, and experts within the United States who saw the virus strike early are offering their advice to other hospitals just starting to feel the effects.
 
Katie Kosko
Patients with acute myeloid leukemia whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza.
 
Jessica Skarzynski
Patients with acute myeloid leukemia often have to undergo transplant during treatment but are susceptible to other side effects, but new research indicates that the use of immunotherapy after these treatments can improve patient outcomes. 
Jessica Skarzynski
Here are the latest highlights from the first CURE Hematology Special Edition issue for 2020.
Debu Tripathy, M.D.
Targeted therapies have changed the landscape of cancer care, and now, hope for remission is a possibility for certain patients with acute myeloid leukemia with new approved therapies.
 
A wave of new targeted therapies expands the options in acute myeloid leukemia.
 
Ryan McDonald
Treatment options for patients with acute myeloid leukemia are limited, especially for older patients, but a new trial looking at novel therapy combinations could change the treatment landscape.
Katie Kosko
Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.
 
Naval Daver, MD
New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×